The first core regulatory circuit identified for ALCL
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
List view / Grid view
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
The Organoid Group have discovered a link between FBXW7 mutations and the EGFR signalling pathway, which could improve colorectal cancer treatments.
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Treatment with Palbociclib and a compound targeting CAD increased survival to 100 percent for selected lymphoma cell lines.